# Paper title:

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

# Orientation Statement:

To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19).

# True Statement:

150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.

# Changes

* Add content
* Masking
* Polarity Shift
* Change Numbers